Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases
Authors:
- Tess TomassenTTTess Tomassen
- Yvonne M. H. Versleijen-JonkersYVYvonne M. H. Versleijen-Jonkers
- Melissa H. S. Hillebrandt-RoeffenMHMelissa H. S. Hillebrandt-Roeffen
- Patricia H. J. Van CleefPCPatricia H. J. Van Cleef
- Thijs van DalenTDThijs van Dalen
- Marije E. WeidemaMWMarije E. Weidema
- Ingrid M. E. DesarIDIngrid M. E. Desar
- Uta FluckeUFUta Flucke
- Joost M. van GorpJGJoost M. van Gorp
Open Access
Abstract
Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular sarcoma with variable aggressive clinical behavior. In this retrospective study, we aimed to investigate prognostic factors based on clinicopathologic findings in a molecularly/immunohistochemically confirmed nationwide multicenter cohort of 57 EHE cases. Patients had unifocal disease (n = 29), multifocal disease (n = 5), lymph node metastasis (n = 8) and/or distant metastasis (n = 15) at the time of diagnosis. The overall survival rate was 71.4% at 1 year and 50.7% at 5 years. Survival did not correlate with sex, age or histopathological parameters. No survival differences were observed between multifocal and metastatic disease, suggesting that multifocality represents early metastases and treatment options are limited in comparison to unifocal disease. In unifocal tumors, survival could be predicted using the risk stratification model of Shibayama et al., dividing the cases into low- (n = 4), intermediate- (n = 15) and high- (n = 3) risk groups. No clinical or histopathological parameters were associated with progressive unifocal disease course. Lymph node metastases at the time of diagnosis occurred in 14.0% of the cases and were mainly associated with tumor localization in the head and neck area, proposing lymph node dissection. In conclusion, our results demonstrate the aggressive behavior of EHE, emphasize the prognostic value of a previously described risk stratification model and may provide new insights regarding tumor focality, therapeutic strategies and prognosis.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendotheliomaHistopathology, 2015
- Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumorOncology Reviews, 2014
- Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 casesDiagnostic Pathology, 2014
- Surgical treatment and results of 62 patients with epithelioid hemangioendothelioma of boneJournal of Surgical Oncology, 2014
- Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendotheliomaGenes, Chromosomes and Cancer, 2013
- Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpointsCancer Genetics, 2012
- Clinical Patterns and Outcome in Epithelioid Hemangioendothelioma With or Without Pulmonary InvolvementChest, 2011
- Identification of a Disease-Defining Gene Fusion in Epithelioid HemangioendotheliomaScience Translational Medicine, 2011
- A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sitesGenes, Chromosomes and Cancer, 2011
- Epithelioid Hemangioendothelioma of the Head and Neck: Role of Podoplanin in the Differential DiagnosisHead and Neck Pathology, 2007